Skip to main content
Clinical Trials/NCT02756390
NCT02756390
Completed
Not Applicable

CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

Dana-Farber Cancer Institute1 site in 1 country56 target enrollmentDecember 2015
ConditionsInsomnia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Insomnia
Sponsor
Dana-Farber Cancer Institute
Enrollment
56
Locations
1
Primary Endpoint
The Insomnia Severity Index (ISI)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. This is a behavioral intervention study, and no medications are involved.

Detailed Description

This study is being done to test the usefulness of a 3-session cognitive-behavioral intervention for improving insomnia in cancer survivors. In this study, the investigators are testing whether this 3-session intervention (Cognitive Behavior Therapy for Insomnia in Cancer Survivors: CBTI-CS) will improve insomnia in cancer survivors whose continue to have insomnia symptoms after receiving sleep hygiene education. In addition to the participants who will be offered sleep hygiene education and the 3-session CBTI-CS,10 additional participants will be recruited to participate in a pilot evaluation of the CBTI-CS intervention delivered via telehealth. This will be a pilot aspect of the study and data from these participants will be for descriptive purposes.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
May 14, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher Recklitis, Ph.D

Christopher Recklitis, PhD, MPH

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age
  • History of a cancer diagnosis
  • No active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next 6 months
  • No surgery planned in the next 6 months
  • Significant insomnia as evidenced by an Insomnia Severity Index score ≥12
  • Able to read and write in English
  • Willing to attend study group sessions
  • Motivated and able to follow the demands of the CBTI-CS program, to keep sleep records, complete self-report symptom reports and make changes in their sleep schedule, including restricting their sleep.

Exclusion Criteria

  • Survivors who report ever being diagnosed with Bipolar Disorder will be excluded.
  • Survivors who report ever being diagnosed with a Seizure Disorder or have experienced a seizure in the past 12 months will be excluded.
  • Intention to adjust (decrease or increase) use of sedative, hypnotic, or over-the-counter medications that can affect sleep during the study period.
  • Have diagnosed, untreated sleep apnea, or sleep apnea suspected by a physician but which has not been evaluated, or other sleep disorder
  • Employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel that involves adjusting to different time zones, or employment in a position that could impact public safety (such as operating heavy machinery)
  • Refusal to modify or reduce excessive alcohol use that is likely to interfere with an individual's sleep.

Outcomes

Primary Outcomes

The Insomnia Severity Index (ISI)

Time Frame: Change from Baseline to 4-weeks post-intervention

The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

Secondary Outcomes

  • Profile of Mood States - Short Form (POMS-SF)(Change from Baseline to 4 & 8 weeks post-intervention)
  • The Insomnia Severity Index (ISI)(Change from Baseline to 8 weeks post-intervention)

Study Sites (1)

Loading locations...

Similar Trials